Morepen Laboratories Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹425Cr
- −6.6% YoY
- −8.8% QoQ
- Net profit
- ₹11Cr
- −69.4% YoY
- −45% QoQ
- Margin
- 6%
- −5 pp YoY
- −3 pp QoQ
Guidance rank: #77 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Morepen Laboratories Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Standalone Gross Revenue (Rs. Q1'FY26 Financials (Standalone):.
From Morepen Laboratories Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Standalone Gross Revenue (Rs. Crores):
- Q1'FY25: 385
- Q1'FY26 (Standalone): 395 (+2.6% YoY)
- Q1'FY26 (Consolidated): 430
- Pharma Business Total Revenue (Rs. Crores):
- Q1'FY25: 250
- Q1'FY26: 235 (-6% YoY)
- Pharma API Revenue (Rs. Crores):
- Q1'FY25: 224
- Q1'FY26: 205 (-8.5% YoY)
- Medical Devices Total Revenue (Rs. Crores):
- Q1'FY25: 443
- Q1'FY26: 496 (+12% YoY)
- Glucometer Sales:
- >1.06 million units sold in Q1'FY26 (72% YoY increase)
- BP Meter Sales:
- 3.37 crores revenue in Q1'FY26 vs. 3.17 crores in Q1'FY25
- Outlook:
2 more points from Morepen Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Plans to add 1000 Medical Representatives over 3 years to strengthen Pharma Business/RX segment (Page 26).
- Pharma Business/Finished Dosages segment: Addition of 2 new product lines in Q1 FY26 indicating capacity/product portfolio expansion (Page 25).
- Exploring new international markets for Medical Devices (Page 17), without disclosed investment amounts or timelines.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Morepen Laboratories Ltd — Quarterly revenue & net profit
Morepen Laboratories Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 425 | 455 | -6.6% | 466 | -8.8% |
| Operating profit (EBITDA) | 24 | 52 | -53.8% | 42 | -42.9% |
| Operating margin | 6% | 11% | -5 pp | 9% | -3 pp |
| Profit before tax | 16 | 48 | -66.7% | 26 | -38.5% |
| Net profit (PAT) | 11 | 36 | -69.4% | 20 | -45% |
| EPS (₹) | 0.20 | 0.71 | -71.8% | 0.37 | -45.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Influx Healthtech (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q1 FY26 results?
Standalone Gross Revenue (Rs. Q1'FY26 Financials (Standalone):.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Plans to add 1000 Medical Representatives over 3 years to strengthen Pharma Business/RX segment (Page 26).
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
